Kevin P. Bateman

Characterization of isomeric sulfonamides using capillary zone electrophoresis coupled with nano-electrospray quasi-MS/MS/MS

The application of capillary electrophoresis/nano-electrospray mass spectrometry to the multi-residue analysis of a large number of sulfonamide antibiotics in milk samples is reported. Tandem mass spectrometric (MS/MS) techniques including precursor ion scans and multiple reaction monitoring were used to identify residues at the low ppb level to the ppt level. Three pairs of isomeric sulfonamides were targeted that differ only in the positions of the nitrogen and oxygen atoms in the heterocyclic aromatic rings of the molecules. Conventional MS/MS analysis yielded no isomer-specific ions. Therefore, a quasi-MS/MS/MS method was applied to overcome these limitations. In-source collision-induced dissociation (CID) was used as a quasi-MS/MS stage to generate ions arising from the heteroaromatic amine moiety. In a second MS/MS step these ions were isolated and made to undergo CID in the collision quadrupole to yield isomer-specific ions. Examples of the application of these methodologies to the analysis of milk extracts are illustrated.

Analytical performance of a high-pressure radio frequency-only quadrupole collision cell with an axial field applied by using conical rods

The effect on triple-quadrupole performance of applying an axial field, in an rf-only quadrupole collision cell operated at pressures sufficiently high that collisional focusing is operating, has been investigated. The advantages of such cells have been shown previously to include increased transmission and much improved resolution in fragment ion spectra relative to the performance of collision cells operating at lower gas pressures. The disadvantages of high-pressure collision cells all derive from the relatively long transit times for the ions, which can be long relative to characteristic times for scanning the first mass filter (precursor ion selector) or for switching its setting in multiple reaction monitoring (MRM) cycles. The present work describes experiments on a high-pressure cell in which an axial field is created through use of conical rather than cylindrical or hyperbolic rods. In addition, results of computations of the electric fields within such a cell, and of ion trajectories through it, are presented. It is shown that application of axial fields of the order of 0. 1 V/cm can remove all hysteresis effects associated with the long ion transit times, and thus provide excellent performance in quantitation work using MRM, as well as in other scan modes. Furthermore, the advantages of collisional focusing in quadrupole collision cells are shown to be unimpaired by these low axial fields.

Generic automated method for liquid chromatography-multiple reaction monitoring mass spectrometry based monoclonal antibody quantitation for preclinical pharmacokinetic studies.

Quantitation of therapeutic monoclonal antibodies (mAb) using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for pharmacokinetic (PK) studies is becoming an essential complement to traditional antibody-based ligand binding assays (LBA). Here we show an automated method to perform LC-MS/MS-based quantitation, with IgG1 conserved peptides, a heavy isotope labeled mAb internal standard, and anti-human Fc enrichment. All reagents in the method are commercially available with no requirement to develop novel assay-specific reagents. The method met traditional quantitative LC-MS/MS assay analytical characteristics in terms of precision, accuracy, and specificity. The method was applied to the pharmacokinetic study of a mAb dosed in cynomolgus monkey, and the results were compared with the immunoassay data. This methodology has the potential to benefit and accelerate the early biopharmaceutical development process, particularly by enabling PK analysis across species and candidate molecules with minimal method development.

Rapid measurement of deuterium-labeled long-chain fatty acids in plasma by HPLC-ESI-MS

Imbalanced fatty acid metabolism contributes significantly to the increased incidence of metabolic disorders. Isotope-labeled fatty acids (2H, 13C) provide efficient means to trace fatty acid metabolism in vivo. This study reports a new and rapid method for the quantification of deuterium-labeled fatty acids in plasma by HPLC-MS. The sample preparation protocol developed required only hydrolysis, neutralization, and quenching steps followed by high-performance liquid chromatography-electrospray ionization-mass spectrometry analysis in negative ion mode using single ion monitoring. Deuterium-labeled stearic acid (d7-C18:0) was synthesized to reduce matrix interference observed with d5 analog, which improved the limit of detection (LOD) significantly, depending on the products analyzed. Linearity > 0.999 between the LOD (100 nM) and 30 μM, accuracy > 90%, precision > 88%, and adequate recovery in the dynamic range were obtained for d7-C18:0 and d7-oleic acid (C18:1). Upon oral dosing of d7-C18:0 in rats, the parent compound and its desaturation and β-oxidation products, d7-C18:1 and d7-C16:0, were circulating with a maximal concentration ranging from 0.6 to 2.2 μM, with significant levels of d7-fatty acids detected for up to 72 h.

Plasma-based approach to measure target engagement for liver-targeting stearoyl-CoA desaturase 1 inhibitors

A positive correlation between stearoyl-CoA desaturase (SCD)1 expression and metabolic diseases has been reported in rodents and humans. These findings indicate that SCD1 is a promising therapeutic target for the chronic treatment of diabetes and dyslipidemia. The SCD1 enzyme is expressed at high levels in several human tissues and is required for the biosynthesis of monounsaturated fatty acids, which are involved in many biological processes. Liver-targeted SCD inhibitors were designed to pharmacologically manipulate SCD1 activity in the liver to avoid adverse events due to systemic inhibition. This article describes the development of a plasma-based SCD assay to assess the level of SCD inhibition, which is defined in this article as target engagement. Essentially, animals are dosed with an exogenous deuterated tracer (d7-stearic acid) as substrate, and the converted d7-oleic acid product is measured to monitor SCD1 inhibition. This study reveals that this plasma-based assay correlates with liver SCD1 inhibition and can thus have clinical utility.

Quantitation of a Therapeutic Antibody in Serum Using Intact Sequential Affinity Capture, Trypsin Digestion, and LC-MS/MS

Large molecule quantitation by LC-MS/MS commonly relies on bottom-up or so-called surrogate peptide measurements to infer the whole-molecule concentration. This can lead to questions about what is actually being measured in the assay (intact drug and/or other drug related material). An intact sequential affinity capture (ISAC) assay was developed utilizing two different immunoaffinity (IA) reagents. The reagents were selective for the heavy and light chain of a monoclonal antibody, which when used consecutively, ensures that only the intact form of the antibody is represented by the surrogate peptide. The approach provided comparable results to a traditional sandwich IA assay indicating similar capture populations. The use of an initial ISAC assessment of affinity capture purification, should add a degree of confidence in the use of a single IA-LC-MS/MS quantitation assay.

Automated DBS microsampling, microscale automation and microflow LC–MS for therapeutic protein PK

AIM Reduce animal usage for discovery-stage PK studies for biologics programs using microsampling-based approaches and microscale LC-MS. METHODS & RESULTS We report the development of an automated DBS-based serial microsampling approach for studying the PK of therapeutic proteins in mice. Automated sample preparation and microflow LC-MS were used to enable assay miniaturization and improve overall assay throughput. Serial sampling of mice was possible over the full 21-day study period with the first six time points over 24 h being collected using automated DBS sample collection. Overall, this approach demonstrated comparable data to a previous study using single mice per time point liquid samples while reducing animal and compound requirements by 14-fold. CONCLUSION Reduction in animals and drug material is enabled by the use of automated serial DBS microsampling for mice studies in discovery-stage studies of protein therapeutics.